IL2RB Remodels the Immune Microenvironment and Promotes the Progression of Esophageal Squamous Cell Carcinoma.

IF 1 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Annals of clinical and laboratory science Pub Date : 2025-05-01

Juan Qin, Yunxiang Tang, Rui Zhu, Xuqin Feng, Jun Bie, Yang Shu, Qikun Lv

{"title":"IL2RB Remodels the Immune Microenvironment and Promotes the Progression of Esophageal Squamous Cell Carcinoma.","authors":"Juan Qin, Yunxiang Tang, Rui Zhu, Xuqin Feng, Jun Bie, Yang Shu, Qikun Lv","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: Esophageal squamous cell carcinoma (ESCA) is a prevalent malignant tumor with poor prognosis. Interleukin 2 receptor beta (IL2RB) has been implicated in various cancers; however, its role in ESCC remains unclear.Methods: We analyzed IL2RB expression in clinical samples and cell lines. The impact of IL2RB on tumor progression was assessed using gain- and loss-of-function approaches, along with in vivo tumor models. In addition, we explored the effect of IL2RB on the immune microenvironment and its potential to modulate the JAK1/STAT5 pathway.Results: IL2RB was found to be significantly upregulated in ESCC tissues compared to normal tissues. Functional studies revealed that IL2RB knockdown inhibited tumor cell proliferation, migration, and invasion, as well as epithelial-mesenchymal transition (EMT). IL2RB was shown to reshape the tumor immune microenvironment by inducing CD8+T cell depletion. Mechanistic investigations indicated that IL2RB activates the JAK1/STAT5 pathway, thereby promoting ESCC progression.Conclusions: Our findings demonstrate that IL2RB plays a critical role in ESCC progression and immune evasion, suggesting its potential as a therapeutic target. Further studies are warranted to explore the clinical application of IL2RB targeting in ESCC treatment.","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"55 3","pages":"309-320"},"PeriodicalIF":1.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of clinical and laboratory science","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Esophageal squamous cell carcinoma (ESCA) is a prevalent malignant tumor with poor prognosis. Interleukin 2 receptor beta (IL2RB) has been implicated in various cancers; however, its role in ESCC remains unclear.

Methods: We analyzed IL2RB expression in clinical samples and cell lines. The impact of IL2RB on tumor progression was assessed using gain- and loss-of-function approaches, along with in vivo tumor models. In addition, we explored the effect of IL2RB on the immune microenvironment and its potential to modulate the JAK1/STAT5 pathway.

Results: IL2RB was found to be significantly upregulated in ESCC tissues compared to normal tissues. Functional studies revealed that IL2RB knockdown inhibited tumor cell proliferation, migration, and invasion, as well as epithelial-mesenchymal transition (EMT). IL2RB was shown to reshape the tumor immune microenvironment by inducing CD8+T cell depletion. Mechanistic investigations indicated that IL2RB activates the JAK1/STAT5 pathway, thereby promoting ESCC progression.

Conclusions: Our findings demonstrate that IL2RB plays a critical role in ESCC progression and immune evasion, suggesting its potential as a therapeutic target. Further studies are warranted to explore the clinical application of IL2RB targeting in ESCC treatment.

本刊更多论文

IL2RB重塑免疫微环境促进食管鳞状细胞癌进展

目的：食管鳞状细胞癌是一种常见的恶性肿瘤，预后较差。白细胞介素2受体β (IL2RB)与多种癌症有关；然而，它在ESCC中的作用仍不清楚。方法：分析临床标本和细胞系中IL2RB的表达。使用功能获得和功能丧失方法以及体内肿瘤模型评估IL2RB对肿瘤进展的影响。此外，我们探索了IL2RB对免疫微环境的影响及其调节JAK1/STAT5通路的潜力。结果：与正常组织相比，ESCC组织中IL2RB明显上调。功能研究显示，IL2RB敲低抑制肿瘤细胞的增殖、迁移和侵袭，以及上皮-间质转化（EMT）。IL2RB通过诱导CD8+T细胞耗竭来重塑肿瘤免疫微环境。机制研究表明，IL2RB激活JAK1/STAT5通路，从而促进ESCC的进展。结论：我们的研究结果表明，IL2RB在ESCC的进展和免疫逃避中起着关键作用，提示其作为治疗靶点的潜力。IL2RB靶向治疗ESCC的临床应用有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of clinical and laboratory science 医学-医学实验技术

CiteScore

1.60

自引率

0.00%

发文量

112

审稿时长

6-12 weeks

期刊介绍： The Annals of Clinical & Laboratory Science welcomes manuscripts that report research in clinical science, including pathology, clinical chemistry, biotechnology, molecular biology, cytogenetics, microbiology, immunology, hematology, transfusion medicine, organ and tissue transplantation, therapeutics, toxicology, and clinical informatics.